Tetrachlorodecaoxide

Tetrachlorodecaoxide
Clinical data
ATC code	D03AX11 (WHO) ;
Identifiers
	IUPAC name Molecular oxygen tetrachlorite hydrate;
CAS Number	92047-76-2 ;
PubChem CID	3000391;
UNII	549BT7IE1Q;
CompTox Dashboard (EPA)	DTXSID40238840 ;
ECHA InfoCard	100.101.959
	(verify)

Tetrachlorodecaoxide (TCDO) is a chlorite-containing, immunomodulatory, macrophage-activating drug whose chemical formula is Cl₄H₂O₁₁.[1][2][3] The drug WF10 (Macrokine, Immunokine) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection.[2] Tetrachlorodecaoxide and WF10 were originally developed by Oxo Chemie.[4]

Tetrachlorodecaoxide / WF10 is used in the management of radiation cystitis,[5] is effective in the treatment of diabetic foot ulcers,[6] and is used in wound healing, where the mechanism of action is activation of the macrophage system, and increasing the partial pressure of oxygen in the wound.[7]

References

"Tetrachlorodecaoxide - Cl4H2O11-4". PubChem. U.S. National Library of Medicine. Retrieved 2016-12-20.
"WF10". Drugprofiles.informa.com. Retrieved 2016-12-20.
Maraprygsavan P, Mongkolsuk J, Arnhold J, Kuehne FW (June 2016). "The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome". Journal of Clinical & Translational Endocrinology. 4: 53–58. doi:10.1016/j.jcte.2016.05.001. PMC 5680448. PMID 29159131.
"About Us - Immunokine® - WF10 - OXO Chemie (Thailand) Co., Ltd". Oxothai.com. Retrieved 2016-12-20.
Smit SG, Heyns CF (April 2010). "Management of radiation cystitis" (PDF). Nature Reviews. Urology. 7 (4): 206–14. doi:10.1038/nrurol.2010.23. hdl:10019.1/14211. PMID 20212517. S2CID 29208541.
Yingsakmongkol N (March 2013). "Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers". Journal of Wound Care. 22 (3): 130–2, 134–6. doi:10.12968/jowc.2013.22.3.130. PMID 23665731.
Parikh R, Bakhshi G, Naik M, Gaikwad B, Jadhav K, Tayade M (September 2016). "The Efficacy and Safety of Tetrachlorodecaoxide in Comparison with Super-oxidised Solution in Wound Healing". Archives of Plastic Surgery. 43 (5): 395–401. doi:10.5999/aps.2016.43.5.395. PMC 5040840. PMID 27689045.

External links

Tetrachlorodecaoxide in the ChemIDplus database
Tetrachlorodecaoxide at Bionity.com
Tetrachlorodecaoxide at Drugs.com

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Tetrachlorodecaoxide - Cl4H2O11-4". PubChem. U.S. National Library of Medicine. Retrieved 2016-12-20.

[informa.com-2] "WF10". Drugprofiles.informa.com. Retrieved 2016-12-20.

[3] Maraprygsavan P, Mongkolsuk J, Arnhold J, Kuehne FW (June 2016). "The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome". Journal of Clinical & Translational Endocrinology. 4: 53–58. doi:10.1016/j.jcte.2016.05.001. PMC 5680448. PMID 29159131.

[4] "About Us - Immunokine® - WF10 - OXO Chemie (Thailand) Co., Ltd". Oxothai.com. Retrieved 2016-12-20.

[5] Smit SG, Heyns CF (April 2010). "Management of radiation cystitis" (PDF). Nature Reviews. Urology. 7 (4): 206–14. doi:10.1038/nrurol.2010.23. hdl:10019.1/14211. PMID 20212517. S2CID 29208541.

[6] Yingsakmongkol N (March 2013). "Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers". Journal of Wound Care. 22 (3): 130–2, 134–6. doi:10.12968/jowc.2013.22.3.130. PMID 23665731.

[7] Parikh R, Bakhshi G, Naik M, Gaikwad B, Jadhav K, Tayade M (September 2016). "The Efficacy and Safety of Tetrachlorodecaoxide in Comparison with Super-oxidised Solution in Wound Healing". Archives of Plastic Surgery. 43 (5): 395–401. doi:10.5999/aps.2016.43.5.395. PMC 5040840. PMID 27689045.